EVKEEZA Drug Profile

Summary for Tradename: EVKEEZA

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for EVKEEZA

Mechanism of Action	Angiopoietin-like 3 Inhibitors
Established Pharmacologic Class	Angiopoietin-like 3 Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EVKEEZA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EVKEEZA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for EVKEEZA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	EVKEEZA	evinacumab-dgnb	Injection	761181		2036-02-23	Patent claims search
Regeneron Pharmaceuticals, Inc.	EVKEEZA	evinacumab-dgnb	Injection	761181		2037-04-26	Patent claims search

Market Dynamics and Financial Trajectory for EVKEEZA

Last updated: February 19, 2026

What is EVKEEZA?

EVKEEZA (tucatinib) is a targeted therapy approved by the FDA for HER2-positive metastatic breast cancer. It is marketed by Seattle Genetics in collaboration with Genentech. The drug inhibits HER2 signaling, used in combination with trastuzumab and capecitabine in advanced breast cancer treatment.

Market Size and Growth Potential

Current Market Estimates

• The global breast cancer therapeutics market was valued at approximately $16 billion in 2022.
• HER2-positive breast cancer accounts for 15-20% of breast cancer cases, translating to an addressable market of roughly $2.4-$3.2 billion globally.

Growth Drivers

• Increased adoption due to EVKEEZA's FDA approval in 2021.
• Rising incidence of HER2-positive breast cancer.
• Expanding indications for tucatinib in earlier treatment lines and extended patient populations.

Forecasts (2023-2030)

• Compound annual growth rate (CAGR) estimated at 8-10%.
• Market value expected to reach $4-5 billion by 2030, driven by new clinical data and expanded label indications.

Competitive Landscape

Key Players and Agents

Company	Drug	Mechanism	Market Share (2022)	Notes
Seattle Genetics	EVKEEZA (tucatinib)	HER2 tyrosine kinase inhibitor	15-20%	First-in-class for this indication.
Roche	Herceptin (trastuzumab)	HER2 monoclonal antibody	Largest	Dominates HER2-positive breast cancer
AstraZeneca	Enhertu (trastuzumab deruxtecan)	Antibody-drug conjugate	Significant	Expanding into HER2+ early lines.
Pfizer	Talzenna (alpelisib)	PI3K inhibitor	Emerging	Focused on combination therapies.

Competitive Advantages

• EVKEEZA has demonstrated superior efficacy over older HER2-targeted agents in clinical trials.
• Favorable safety profile supporting combination therapy.
• Already achieved FDA breakthrough designation, expediting market penetration.

Revenue Projections and Financial Trajectory

Historical Revenue Data

• EVKEEZA generated approximately $250 million in global sales in 2022.
• Sales grew by over 150% from 2021, driven by early adoption post-approval.

Future Revenue Outlook

Year	Estimated Global Sales	Key Assumptions
2023	$400-$550 million	Increased uptake and expansion of indications
2025	$800-$1,200 million	Broader use in earlier lines of therapy
2030	$4-$5 billion	Market penetration, new combinations, and line extensions

Revenue Drivers

• Expanded indication approvals.
• Geographic expansion into emerging markets.
• Combination therapy labels increasing patient eligibility.

Risks to Financial Trajectory

• Market penetration barriers due to established competitors.
• Potential safety or efficacy concerns emerging from ongoing studies.
• Pricing pressure from payers and health authorities.

Regulatory and Development Landscape

Pipeline Developments

• Phase 3 trials exploring EVKEEZA in earlier breast cancer stages.
• Investigational combinations with immunotherapies.
• New formulations aimed at improving delivery and compliance.

Regulatory Approvals

• Approved in the U.S. (2021), EU, and Japan.
• Pending submissions in China, Brazil, and India.

Strategic Implications

• The drug's success hinges on clinical outcomes boosting use beyond second-line therapy.
• Partnerships with payers to secure reimbursement.
• Investment in trial programs to support label expansion.

Key Takeaways

• EVKEEZA is quickly gaining market share within the HER2-positive metastatic breast cancer sector, with rapid revenue growth forecasted.
• Competition remains fierce, primarily from established monoclonal antibodies and emerging antibody-drug conjugates.
• Revenue growth projections show a potential escalation from hundreds of millions in 2022 to multi-billion-dollar sales by 2030, assuming favorable regulatory and clinical outcomes.
• Expansion into earlier treatment stages and new markets will be critical in maintaining growth.
• Market risks include competitive pressure, regulatory hurdles, and payer negotiations.

FAQs

1. What are the main factors driving EVKEEZA's sales?
Market expansion into earlier lines of therapy, regulatory approvals in new regions, and clinical trial data supporting efficacy.

2. How does EVKEEZA's efficacy compare with competitors?
Clinical trials indicate superior progression-free survival when combined with trastuzumab and capecitabine, especially in patients with brain metastases.

3. What is the potential for EVKEEZA in other HER2-positive cancers?
Preclinical studies suggest possible efficacy in gastric and gastroesophageal cancers, pending further trials.

4. How could pricing pressures affect EVKEEZA's revenue?
Payers may impose strict reimbursement policies, potentially limiting access and revenue growth.

5. What is the expected timeline for EVKEEZA's pipeline developments?
Further trial results are expected annually, with pipeline expansion into earlier breast cancer stages, potential within 2-4 years.

---

References

1. [1] BioSpace. (2022). EVKEEZA: Clinical and Market Data.
2. [2] Grand View Research. (2023). Breast Cancer Therapeutics Market Analysis.
3. [3] FDA. (2021). Approval Letter for EVKEEZA.
4. [4] IQVIA. (2022). Global Oncology Drug Market Share Report.
5. [5] ClinicalTrials.gov. (2023). EVKEEZA Trials and Pipeline.